ATN-161 trifluoroacetate salt is primarily used in research and therapeutic applications due to its role as an integrin inhibitor. It is studied for its potential to disrupt integrin-mediated signaling pathways, which are crucial in processes like angiogenesis, cancer metastasis, and inflammation. In preclinical studies, it has shown promise in inhibiting tumor growth and metastasis by targeting specific integrins involved in cell adhesion and migration. Additionally, it is being explored for its potential in treating conditions like fibrosis and inflammatory diseases, where integrin signaling plays a significant role. Its application in drug development focuses on creating targeted therapies for these complex diseases.